Precocious puberty — branching viva

Opening framework

My framework rests on one decision: who is driving the axis? Precocious puberty is secondary sexual characteristics before 8 years in girls and before 9 years in boys. If the hypothalamic–pituitary–gonadal axis is genuinely switched on, the process is central (GnRH-dependent), gonadotropins rise, and a GnRH analog will switch it back off. If a sex-steroid source is operating outside the axis, the process is peripheral (GnRH-independent), gonadotropins are suppressed, and a GnRH analog is useless. I confirm with a bone age and a basal-then-stimulated gonadotropin panel, I image the brain in every boy and in girls under 6 years, and I match the treatment to the driver. The two preventable harms are a short adult stature from unchecked sex steroids and a missed central nervous system lesion. [1] [2]

The index case — the 6-year-old girl

This girl's consonant sequence — thelarche, then adrenarche, then the growth spurt — and her bone age advanced by two and a half years point to central disease, and the pubertal luteinising-hormone peak on GnRH stimulation confirms it. Because she is under 6 years, I order a brain MRI to seek a hypothalamic hamartoma or tumour; if it is normal, the disease is idiopathic central precocious puberty. Because the course is progressive with height compromise, I treat with a GnRH analog — a leuprolide depot or a histrelin implant — to suppress gonadotropins, halt bone-age acceleration and preserve adult height. The principal measurable goal is adult height, and I monitor growth velocity and bone age every three to six months, stopping the analog when further height gain is negligible. [1] [3]

Branch 1 — the 4-year-old boy with gelastic seizures

The enlarged testis (6 mL) in this boy confirms a gonadotropin-driven central process, because the testis cannot grow without luteinising hormone. Every boy with central disease earns a brain MRI, and here the MRI shows a hypothalamic hamartoma — the classic lesion — which both drives the puberty (as an ectopic GnRH- or kisspeptin-secreting focus) and causes his gelastic seizures. The puberty is managed with a GnRH analog exactly as in idiopathic disease; the hamartoma itself is benign and is not resected for the puberty, but when the gelastic seizures are intractable I involve a specialist neurosurgical or radiosurgical service for possible disconnection. [1] [2]

Branch 2 — the 3-year-old girl with cafe-au-lait macules

This is McCune-Albright syndrome: a postzygotic activating Gs-alpha mutation producing the triad of polyostotic fibrous dysplasia, coast-of-Maine cafe-au-lait macules, and autonomous endocrine hyperfunction — here peripheral precocious puberty. Her suppressed gonadotropins with high oestrogen confirm that the axis is bypassed by autonomous ovarian function, which is exactly why a GnRH analog cannot work — the axis is already switched off, so there is nothing further to suppress. I treat with an aromatase inhibitor such as letrozole (or tamoxifen) to lower the oestrogen, and I bring in a specialist multidisciplinary team for the bone disease and the other endocrine axes. [8] [1]

Branch 3 — the family weighing GnRH-analog therapy

I counsel the family on three points. First, the height rationale: without treatment the sex steroids will fuse the growth plates early and the tall child will become the short adult; a GnRH analog halts that and preserves adult height. Second, the safety: the depots are well established, with injection-site reactions and a transient hormone flare the main acute effects, and a modern long-term trial confirms an acceptable safety profile. Third, the stopping point: the analog is continued until the bone age reaches the point where further height gain is negligible — commonly around a bone age of 11 years in girls — at which point treatment stops and puberty resumes in step with peers. Throughout, I offer psychological support for the child who looks older than her classmates. [3] [2]

Closing — the trap to avoid

The cardinal trap is treating a peripheral cause with a GnRH analog: it cannot work, because the suppressed axis has nothing further to down-regulate, and the autonomous source keeps eroding height while the clinician believes action has been taken. The defence is the gonadotropins — a suppressed luteinising hormone and follicle-stimulating hormone with a high sex steroid is peripheral disease, and I treat it at its source, never at the pituitary. [1] [8]